Company intelligence / Profile preview
United BioPharma
- Ownership
- Private
- Development stage
- Other
Overview
United BioPharma’s lead asset is semzuvolimab, a monoclonal antibody targeting CD4 for HIV infections in Phase 3 trials. The company also has clinical-stage assets targeting HER2-positive breast cancer and other indications. UBPs proprietary platform enables the rapid development and manufacturing of high-quality monoclonal antibodies. Recent milestones include US FDA approval for a Phase 2 trial in recurrent genital herpes with UB‑621 and IND approval from China NMPA for a multi-center Phase 3 trial with UB‑421 in HIV-infected adults
- Therapeutic areas
- PulmonologyOncologyInfectious Diseases
- Modalities
- Monoclonal antibodyBiologicRecombinant protein
- Industry
- Biotech
Drug pipeline
10 assets9 more assets in the full pipeline.
Partnerships
Beyond the preview
Go deeper on United BioPharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on United BioPharma.